ABERA BIOSCIENCE AB
Research ABERA BIOSCIENCE AB (8WK) on Bullrun: market cap EUR 16.52M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker8WK
- ExchangeF
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 16.52M
- Financial periodQ1 2026
- RevenueSEK 0
- Net income-SEK 5.80M
- Free cash flow-SEK 7.44M
Valuation Snapshot
latest market cap is EUR 16.52M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 10.45M | -SEK 3.68M | n/a | -0.57 | SEK 23.49M | n/a | SEK 19.29M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 16.52M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About ABERA BIOSCIENCE AB
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ABERA BIOSCIENCE AB's market cap?
ABERA BIOSCIENCE AB's market capitalization is EUR 16.52M.
What does ABERA BIOSCIENCE AB do?
Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC, Covid-19, and Tuberculosis.